Mental Health
124 Advancements in Antidepressants
Sydney Billman
Introduction
Major depressive disorder has long been a heavy burden for millions of individuals, affecting their daily lives and well-being. Effective treatments for this condition were not discovered until the 1950s, with the first antidepressant introduced in 1958. Since then, advancements in medication have significantly transformed the treatment options available for individuals diagnosed with depression. Over the years, these drugs have demonstrated significant benefits, though they have also sparked important discussions and concerns regarding their long-term effects, overuse, and placebo effects. As ongoing research into depression and its treatments progresses, concerns and risks may be alleviated, paving the way for the ultimate goal of societal advancement.
Connection to Science, Technology, and society
The advancement in depression medication is connected to the various fields of science, technology, and society. The development of new antidepressants is grounded in scientific research on the brain. As neuroscience and pharmacology have advanced, an increasing amount of research has enabled scientists to gain a deeper understanding of depression and, in turn, develop more effective treatments. Technology has been crucial in the development of these medications. Innovations in drug delivery systems, like the intranasal esketamine treatment, have improved the range, as well as effectiveness, of treatment options. As the availability of more effective antidepressants has increased, it has had a profound effect on society, improving the lives of millions of people. As antidepressants become increasingly accessible and effective, they will play a pivotal role in advancing societal well-being and progress.
Discovery of the First Antidepressant
In the 1950s, a significant breakthrough in depression treatment emerged with the development of the monoamine hypothesis. The monoamine hypothesis proposed that patients with depression have depleted concentrations of three monoamines: serotonin, norepinephrine, and dopamine. Through this hypothesis, the discovery of the mechanism of monoamine oxidase (MAO) inhibitors proved to be the first progress towards treating depression. The first antidepressant was discovered through an attempt to treat tuberculosis. Chemists developed isonicotinyl hydrazide, also known as isoniazid, as a treatment option for tuberculosis. In 1953, while developing more antitubercular compounds, Herbert Fox and John T. Gibas synthesized isopropyl-isonicotinyl hydrazide, also known as iproniazid,
as a derivative of isoniazid. The tuberculosis patients who were being treated with iproniazid were showing side effects that included euphoria, increased appetite, and improved sleep. In 1958, a clinical study was conducted on patients with depression. The patients were given iproniazid for several weeks and monitored closely. The findings reported significant improvemen